Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease
Preische, Oliver, Sohrabi, Hamid R. , Gräber, Susanne, Ringman, John M. , Martins, Ralph N. , Rossor, Martin N. , Fox, Nick N., Graff‐Radford, Neill R. , Xiong, Chengjie , Danek, Adrian , Vöglein, Jonathan , Salloway, Stephen , Xiong, Chengjie , Benzinger, Tammie L.S. , Buckles, Virginia, Masters, Colin L. , Bateman, Randall J. , Morris, John C. , Laske, Christoph , (DIAN), Dominantly Inherited Alzheimer Network, Fox, Nick C. , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Morris, John C , Müller, Stephan, Jucker, Mathias , McDade, Eric , Schofield, Peter R. , Ghetti, Bernardino , Fox, Nick N., Sperling, Reisa Anne , (DIAN), Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | September 25, 2018 | Volume: 14 | Issue: 11 | Pages: 1427-1437

10.1016/j.jalz.2018.06.3059 | PMID 30266303 Get It

AbstractIntroductionLittle is known about effects of physical activity (PA) in genetically driven early‐onset autosomal dominant Alzheimer's disease (AD).MethodsA total of 372 individuals participating at the Dominantly Inherited Alzheimer Network study were examined to evaluate the cross‐sectional relationship of PA with cognitive performance, functional status, cognitive decline, and AD biomarkers in cerebrospinal fluid. Mutation carriers were categorized as high or low exercisers according to WHO recommendations.ResultsMutation carriers with high PA showed significantly better cognitive and functional performance and significantly less AD‐like pathology in cerebrospinal fluid than individuals with low PA. Mutation carriers with high PA scored 3.4 points better on Mini Mental State Examination at expected symptom onset and fulfilled the diagnosis of very mild dementia 15.1 years later compared with low exercisers.DiscussionThese results support a beneficial effect of PA on cognition and AD pathology even in individuals with genetically driven autosomal dominant AD.
Alternative methods for virtual heart transplant—Size matching for pediatric heart transplantation with and without donor medical images available
Plasencia, Jonathan D. , Kamarianakis, Yiannis , Karamlou, Tara , Park, Susan S., Nigro, John J. , Frakes, David , Pophal, Stephen , Lagerstrom, Carl F., Velez, Daniel A. , Zangwill, Steven , Ryan, Justin

Mayo Clinic

Pediatric Transplantation | September 24, 2018 | Volume: 22 | Issue: 8 | Pages: No page available

10.1111/petr.13290 | PMID 30251298 Get It

Abstract Background Listed pediatric heart transplant patients have the highest solid‐organ waitlist mortality rate. The donor‐recipient body weight ( DRBW ) ratio is the clinical standard for allograft size matching but may unnecessarily limit a patient's donor pool. To overcome DRBW ratio limitations, two methods of performing virtual heart transplant fit assessments were developed that account for patient‐specific nuances. Method 1 uses an allograft total cardiac volume ( TCV ) prediction model informed by patient data wherein a matched allograft 3‐D reconstruction is selected from a virtual library for assessment. Method 2 uses donor images for a direct virtual transplant assessment. Methods Assessments were performed in medical image reconstruction software. The allograft model was developed using allometric/isometric scaling assumptions and cross‐validation. Results The final predictive model included gender, height, and weight. The 25th‐, 50th‐, and 75th‐percentiles for TCV percentage errors were −13% (over‐prediction), −1%, and 8% (under‐prediction), respectively. Two examples illustrating the potential of virtual assessments are presented. Conclusion Transplant centers can apply these methods to perform their virtual assessments using existing technology. These techniques have potential to improve organ allocation. With additional experience and refinement, virtual transplants may become standard of care for determining suitability of donor organ size for an identified recipient.
Automated Extraction of Microbial DNA From Formalin-Fixed, Paraffin-Embedded Tissue Using the Siemens Tissue Preparation System
Thorvilson, Jill N., Berry, Jonathan, Buckwalter, Seanne P., Lynne, Sloan, Rucinski, Stefanea L., Koelsch, Jolene M. , Pritt, Bobbi S. , Wengenack, Nancy L. , Pritt, Bobbi S , Saadalla, Abdulrahman , Schuetz, Audrey N.

Mayo Clinic

American Journal of Clinical Pathology | September 21, 2018 | Volume: 150 | Issue: suppl_1 | Pages: S151-S152

10.1093/ajcp/aqy112.357 Get It

B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, Taku , Kim, Sunghee , Pieper, Karen S. , Blanco, Rosalia , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Mahaffey, Kenneth W. , Singer, Daniel E. , Piccini, Jonathan P. , Steinberg, Benjamin A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Freeman, James V. , Steinberg, Benjamin A. , Peterson, Eric D.

Mayo Clinic

Heart | September 18, 2018 | Volume: 105 | Issue: 5 | Pages: 370-377

10.1136/heartjnl-2018-313642 | PMID 30228248 Get It

Objective The association with B-type natriuretic peptide (BNP), disease progression and outcomes in patients with atrial fibrillation (AF) has not been thoroughly investigated. Methods We evaluated the association between BNP levels and outcomes, including AF progression, composite outcome of major adverse cardiovascular or neurological events (MACNE) and major bleeding, via pooled logistic regression and Cox frailty models in Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry. AF progression was defined as either paroxysmal becoming persistent or permanent, or persistent becoming permanent at any follow-up. Results Among 13 375 patients with AF, 2797 with BNP values at baseline (median age (IQR), 72.0 (63.0–80.0) years; 43.0% women; median BNP, 238 (102–502) ng/L; 42.3% prior heart failure) were included in the models evaluating the association between BNP levels and MACNE or major bleeding. Of these, 1282 patients with paroxysmal or persistent AF at baseline were analysed in AF progression model. The likelihood of AF progression (adjusted OR, 1.11 for every 100 ng/mL; 95% CI 1.03 to 1.19) and MACNE (adjusted HR, 1.11 for every doubling in BNP values; 95% CI 1.01 to 1.22) increased with BNP concentration, while the elevated BNP values were not associated with increased risks of major bleeding. BNP values improved the risk prediction of AF progression and MACNE when added to conventional risk estimates. Conclusions BNP levels are associated with increased risk of AF progression and cardiovascular outcomes in patients with AF. Further studies are required to assess whether biomarker-based risk stratification improves patient outcomes. Clinical trial registration NCT01701817 .
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam, Jeffrey B. , Holmes, DaJuanicia N. , Thomas, Laine , Mahaffey, Kenneth W. , Kowey, Peter R. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Singer, Daniel E. , Blanco, Rosalia , Piccini, Jonathan P. , Pokorney, Sean D. , Hylek, Elaine M. , Fonarow, Gregg C. , Gersh, Bernard J. , Freeman, James V. , Naccarelli, Gerald V. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 17, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.008928 | PMID 30371218 Get It

Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) with baseline renal function and follow‐up data were included (N=9019). CKD was defined as an estimated creatinine clearance <60 mL /min. Patient characteristics were compared by CKD status, and Cox proportional hazards modeling was used to examine the association between oral anticoagulant ( OAC ) use and outcomes and antiarrhythmic drug use and outcomes stratified by CKD stages. At enrollment, 3490 (39%) patients had an estimated creatinine clearance <60 mL /min. Patients with CKD were older and had higher CHA 2 DS 2 VAS c and Anticoagulant and Risk Factors in Atrial Fibrillation (ATRIA) scores. A rhythm control strategy was selected less frequently in patients with CKD , while OAC use was lower among Stage IV and V CKD patients. After adjustment, no significant interaction was noted for OAC and CKD on all‐cause mortality ( P =0.5442) or cardiovascular death ( P =0.1233), although a trend for increased major bleeding ( P =0.0608) and stroke, systemic embolism or transient ischemic attack ( P =0.0671) was observed. No interaction was noted for antiarrhythmic drug use and CKD status on all‐cause mortality ( P =0.9706), or stroke, systemic embolism or transient ischemic attack ( P =0.4218). Conclusions Patients with atrial fibrillation and CKD are less likely to be treated with rhythm control. Patients with advanced CKD are less likely to receive OAC . Finally, outcomes with OAC in patients with advanced CKD may be materially different with higher rates of both bleeding and stroke.
Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death
Madhavan, Malini , Waks, Jonathan W. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mehta, Ramila A. , Hodge, David O. , Higgins, Angela , Webster, Tracy L., Witt, Chance M. , Cha, Yong‐Mei , Higgins, Angela Y. , Noseworthy, Peter A. , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 17, 2018 | Volume: 9 | Issue: 3 | Pages: No page available

10.1161/circep.115.003283 | PMID 26921377 Get It

Background— The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF) ≤35% and clinical heart failure is well established. However, outcomes after replacement of the ICD generator in patients with recovery of EF to >35% and no previous therapies are not well characterized. Methods and Results— Between 2001 and 2011, generator replacement was performed at 2 tertiary medical centers in 253 patients (mean age, 68.3±12.7 years; 82% men) who had previously undergone ICD placement for primary prevention but subsequently never received appropriate ICD therapy. EF had recovered to >35% in 72 of 253 (28%) patients at generator replacement. During median (quartiles) follow-up of 3.3 (1.8–5.3) years after generator replacement, 68 of 253 (27%) experienced appropriate ICD therapy. Patients with EF ≤35% were more likely to experience ICD therapy compared with those with EF >35% (12% versus 5% per year; hazard ratio, 3.57; P =0.001). On multivariable analysis, low EF predicted appropriate ICD therapy after generator replacement (hazard ratio, 1.96 [1.35–2.87] per 10% decrement; P =0.001). Death occurred in 25% of patients 5 years after generator replacement. Mortality was similar in patients with EF ≤35% and >35% (7% versus 5% per year; hazard ratio, 1.10; P =0.68). Atrial fibrillation (3.24 [1.63–6.43]; P <0.001) and higher blood urea nitrogen (1.28 [1.14–1.45] per increase of 10 mg/dL; P <0.001) were associated with mortality. Conclusions— Although approximately one fourth of patients with a primary prevention ICD and no previous therapy have EF >35% at the time of generator replacement, these patients continue to be at significant risk for appropriate ICD therapy (5% per year). These data may inform decisions on ICD replacement.
Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?
Khan, Muhammad Shahzeb , Usman, Muhammad , Siddiqi, Tariq Jamal , Murad, M. Hassan , Mookadam, Farouk , Figueredo, Vincent M. , Benza, Raymond L. , Rich, Jonathan D. , Benza, Raymond L. , Murad, M Hassan , Usman, Muhammad Shariq , Khan, Safi U. , Krasuski, Richard A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 16, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circoutcomes.118.004757 | PMID 30354550 Get It

Background Data about anticoagulation in pulmonary arterial hypertension (PAH) patients are inconsistent. The objective of this study was to examine the impact of adjunctive oral anticoagulants in patients with PAH through meta-analysis, and to further assess whether response differs by PAH subtype. Methods and Results Cochrane CENTRAL, Medline, and Scopus databases were searched for randomized or nonrandomized studies that assessed the association between anticoagulation and outcomes in patients with PAH. Hazard ratios (HRs) for mortality were pooled using the random effects model. Subgroup analyses were performed for type of PAH and study design. Twelve nonrandomized studies, at moderate risk of bias, were included. These consisted of 2512 patients (1342 receiving anticoagulation and 1170 controls). Anticoagulation significantly reduced mortality in the overall PAH cohort (HR, 0.73 [0.57, 0.93]; P =0.001; I 2 =64%). On subgroup analysis, a significant mortality reduction was seen in idiopathic PAH patients (HR, 0.73 [0.56, 0.95]; P =0.02; I 2 =46%), whereas no significant difference was observed in connective tissue disease–related PAH (HR, 1.16 [0.58, 2.32]; P =0.67; I 2 =71%). Sensitivity analysis specific to scleroderma-associated PAH demonstrated a significant increase in mortality with anticoagulant use (HR, 1.58 [1.08, 2.31]; P =0.02; I 2 =9%). Conclusions This meta-analysis shows that use of anticoagulation may improve survival in idiopathic PAH patients, while increasing mortality when used in scleroderma-associated-PAH patients. Currently, no randomized clinical trials have been published, and until randomized data are available, anticoagulant use in PAH should be tailored to PAH subtype.